This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

1 Jul 2014

BMS Issues Voluntary Recall of Coumadin for Injection

Bristol-Myers Squibb Company (BMS) is voluntarily recalling six lots of Coumadin for injection, 5 mg single-use vials in the US. This recall is a precautionary measure based on the company’s investigation of visible particulate matter found in a small number of Coumadin for injection unreleased samples. BMS believes the safety risk to patients is low, and is further mitigated by the product’s prescribing information advising that intravenous drug products be inspected visually prior to administration.


Injected particulate metallic and non-metallic cellulose material can cause serious and potentially fatal adverse reactions such as embolization. Allergic reactions to the foreign material could also occur. To date, there have been no product complaints or adverse events reported to BMS related to this issue.

Coumadin for injection was discontinued in early April 2014. The oral formulation, Coumadin tablets, is not affected by this recall.

Related News